Подписаться
Dr. Bhagwan Yadav, PhD
Dr. Bhagwan Yadav, PhD
University of Helsinki
Подтвержден адрес электронной почты в домене helsinki.fi
Название
Процитировано
Процитировано
Год
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
B Yadav, K Wennerberg, T Aittokallio, J Tang
Computational and Structural Biotechnology Journal 13, 504-513, 2015
7192015
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaISM Approach to Therapy Selection
T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ...
Cancer discovery 3 (12), 1416-1429, 2013
4702013
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ...
Scientific reports 4 (1), 1-10, 2014
3582014
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ...
Haematologica 105 (3), 708, 2020
1572020
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
O Kauko, CM O’Connor, E Kulesskiy, J Sangodkar, A Aakula, S Izadmehr, ...
Science translational medicine 10 (450), eaaq1093, 2018
1562018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ...
Nature Communications 9 (1), 1567, 2018
1382018
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ...
Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017
1322017
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid LeukemiaAML Functional Molecular Precision Medicine
D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ...
Cancer Discovery 12 (2), 388-401, 2022
1302022
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
A Schrader, G Crispatzu, S Oberbeck, P Mayer, S Pützer, J von Jan, ...
Nature communications 9 (1), 1-22, 2018
1072018
Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection
OV Denisova, L Kakkola, L Feng, J Stenman, A Nagaraj, J Lampe, ...
Journal of Biological Chemistry 287 (42), 35324-35332, 2012
1052012
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways
J Tang, L Karhinen, T Xu, A Szwajda, B Yadav, K Wennerberg, ...
PLoS computational biology 9 (9), e1003226, 2013
1022013
Consistency in drug response profiling
JP Mpindi, B Yadav, P Östling, P Gautam, D Malani, A Murumägi, ...
Nature 540 (7631), E5-E6, 2016
1012016
Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer
K Saeed, V Rahkama, S Eldfors, D Bychkov, JP Mpindi, B Yadav, ...
European urology 71 (3), 319-327, 2017
1002017
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ...
Leukemia 31 (2), 301-309, 2017
1002017
Breeze: an integrated quality control and data analysis application for high-throughput drug screening
S Potdar, A Ianevski, JP Mpindi, D Bychkov, C Fiere, P Ianevski, B Yadav, ...
Bioinformatics 36 (11), 3602-3604, 2020
992020
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ...
Leukemia, 2017
972017
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
P Gautam, L Karhinen, A Szwajda, SK Jha, B Yadav, T Aittokallio, ...
Molecular cancer 15 (1), 1-16, 2016
752016
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1
O Kauko, SY Imanishi, E Kulesskiy, L Yetukuri, TD Laajala, M Sharma, ...
Journal of Biological Chemistry 295 (13), 4194-4211, 2020
632020
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ...
Leukemia 33 (6), 1360-1372, 2019
602019
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ...
Leukemia 31 (5), 1187-1195, 2017
572017
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20